Literature DB >> 12911785

Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population.

I Sayers1, S Barton, S Rorke, J Sawyer, Q Peng, B Beghé, S Ye, T Keith, J B Clough, J W Holloway, A P Sampson, S T Holgate.   

Abstract

BACKGROUND: 5-Lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) are essential for cysteinyl-leukotriene (cys-LT) production, critical mediators in asthma.
OBJECTIVE: We sought to identify novel promoter polymorphisms within the FLAP (ALOX5AP) gene promoter and test the role of these and the previously identified 5-LO (ALOX5) Sp1 promoter polymorphism in asthma susceptibility.
METHODS: To assess genetic association with asthma phenotypes, we genotyped 341 Caucasian families (containing two asthmatic siblings) and non-asthmatic control subjects (n=184). Genetic association was determined by case-control and transmission disequilibrium test (TDT) analyses. To determine the functional role of polymorphisms on basal transcription, we generated ALOX5AP-promoter-luciferase constructs and transiently transfected human HeLa cells.
RESULTS: A novel G/A substitution at -336 bp and a poly(A) repeat (n=19 or 23) at position -169 to -146 bp were identified in the ALOX5AP promoter. Genotyping found the -336 A and poly(A19) alleles at frequencies of q=0.06 and 0.12, respectively. No ALOX5AP allele was associated with asthma or asthma-related phenotypes in case-control or TDT analyses. ALOX5AP-promoter-luciferase analyses did not support a functional role of the -336 or poly(A) polymorphism in determining basal transcription. The ALOX5 Sp1 polymorphism was predominantly homozygous wild-type 5/5 (frequency q=0.70) and heterozygous 4/5 (q=0.23) genotypes and no allele was associated with asthma or asthma-related phenotypes.
CONCLUSION: Taken together, these data do not support a significant role for these polymorphisms in genetic susceptibility to asthma in the Caucasian population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911785     DOI: 10.1046/j.1365-2222.2003.01733.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  15 in total

Review 1.  Pharmacotherapy of asthma.

Authors:  Martin M Zdanowicz
Journal:  Am J Pharm Educ       Date:  2007-10-15       Impact factor: 2.047

2.  Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.

Authors:  John J Lima; Shu Zhang; Audrey Grant; Lianhe Shao; Kelan G Tantisira; Hooman Allayee; Jianwei Wang; James Sylvester; Janet Holbrook; Robert Wise; Scott T Weiss; Kathleen Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-11-17       Impact factor: 21.405

3.  Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry.

Authors:  Alexa J Resler; Karen W Makar; Laura Heath; John Whitton; John D Potter; Elizabeth M Poole; Nina Habermann; Dominique Scherer; David Duggan; Hansong Wang; Noralane M Lindor; Michael N Passarelli; John A Baron; Polly A Newcomb; Loic Le Marchand; Cornelia M Ulrich
Journal:  Carcinogenesis       Date:  2014-06-07       Impact factor: 4.944

Review 4.  G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective.

Authors:  Miles D Thompson; Jun Takasaki; Valérie Capra; G Enrico Rovati; Kathy A Siminovitch; W McIntyre Burnham; Thomas J Hudson; Yohan Bossé; David E C Cole
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer.

Authors:  Nina Habermann; Cornelia M Ulrich; Abbie Lundgreen; Karen W Makar; Elizabeth M Poole; Bette Caan; Richard Kulmacz; John Whitton; Rachel Galbraith; John D Potter; Martha L Slattery
Journal:  Genes Nutr       Date:  2012-06-08       Impact factor: 5.523

6.  Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population.

Authors:  Seung-Hyun Kim; Jeong-Hee Choi; J W Holloway; Chang-Hee Suh; Dong-Ho Nahm; Eun-Ho Ha; Choon-Sik Park; Hae-Sim Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

7.  Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.

Authors:  Sarah E Kleinstein; Laura Heath; Karen W Makar; Elizabeth M Poole; Brenna L Seufert; Martha L Slattery; Liren Xiao; David J Duggan; Li Hsu; Karen Curtin; Lisel Koepl; Jill Muehling; Darin Taverna; Bette J Caan; Christopher S Carlson; John D Potter; Cornelia M Ulrich
Journal:  Genes Chromosomes Cancer       Date:  2013-02-12       Impact factor: 5.006

8.  The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos.

Authors:  M Via; A De Giacomo; H Corvol; C Eng; M A Seibold; C Gillett; J Galanter; S Sen; H Tcheurekdjian; R Chapela; J R Rodríguez-Santana; W Rodríguez-Cintrón; S Thyne; P C Avila; S Choudhry; E González Burchard
Journal:  Clin Exp Allergy       Date:  2010-01-11       Impact factor: 5.018

Review 9.  Pharmacogenetic approaches in the treatment of asthma.

Authors:  Ian Sayers; Ian P Hall
Journal:  Curr Allergy Asthma Rep       Date:  2005-03       Impact factor: 4.919

Review 10.  Update on recent advances in the management of aspirin exacerbated respiratory disease.

Authors:  Nami Shrestha Palikhe; Joo-Hee Kim; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.